Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TCR2 Therapeutics Inc. - Common Stock (NQ:TCRR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.490 (52)
Ask (Size) 1.630 (51)
Prev. Close 1.480
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 39,261,745
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
News headline image
Recap: TCR2 Therapeutics Q1 Earnings ↗
 
Via Benzinga

Performance

More News

Read More
News headline image
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
What To Know About Jefferies's Downgrade of TCR2 Therapeutics ↗
Via Benzinga
News headline image
4 Analysts Have This to Say About TCR2 Therapeutics ↗
Via Benzinga
News headline image
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company ↗
Via Benzinga
News headline image
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗
Via Benzinga
News headline image
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗
Via Benzinga
News headline image
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗
Via Benzinga
News headline image
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗
Via Benzinga
News headline image
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗
Via Benzinga
News headline image
Why Is TCR2 Therapeutics Stock Trading Higher Today? ↗
Via Benzinga
News headline image
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
Via Spotlight Growth
News headline image
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? ↗
Via InvestorPlace
News headline image
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is TCR2 Therapeutics Inc. - Common Stock publicly traded?
Yes, TCR2 Therapeutics Inc. - Common Stock is publicly traded.
What exchange does TCR2 Therapeutics Inc. - Common Stock trade on?
TCR2 Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TCR2 Therapeutics Inc. - Common Stock?
The ticker symbol for TCR2 Therapeutics Inc. - Common Stock is TCRR on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.